Dr Adele Hosseini has been appointed interim CEO of Cerulea Clinical Trials and will start her new role on Monday 19 May.

Dr Hosseini, who has most recently held the role of Global Head of Scientific Services at George Clinical, is relocating from Sydney to take on the role while the recruitment of a permanent CEO for Cerulea is underway.

Cerulea Clinical Trials Chair, Professor Keith Martin, welcomed Dr Hosseini to the interim CEO role.

“Dr Adele Hosseini brings deep experience in the pharmaceutical, biotech and clinical research industries to Cerulea from previous roles at ARCS Australia, Bod Science and Sirtex Technologies,’’ he said.

Professor Martin said Dr Hosseini’s strong expertise in clinical trials and has led both commercial and investigator-initiated studies.

In addition to her many executive roles, she also has strong Board and governance experience and is currently Chair of the Australian and New Zealand College of Cannabinoid Practitioners.

Dr Hosseini said she looked forward to collaborating with Cerulea staff, industry sponsors, research investigators and clinicians to deliver high quality clinical research during transition period to the new CEO.

“I look forward to working with the Cerulea team, to build on their achievements in establishing a new ophthalmic clinical trials centre and lay a solid foundation for the incoming CEO.’’